PurPose: Treatment of post-operative pain after breast reconstruction remains a significant challenge for plastic surgeons. Liposomal bupivacaine (LB, Exparel Pacira Pharmaceuticals, Inc., Parsippany, NJ) has been proven to effectively relieve pain in the immediate postoperative period. The purpose of our study is to explore the effects of intraoperatively delivered LB on postoperative narcotic use in women undergoing autologous and implant-based breast reconstruction.
Methods: Patients undergoing abdominally-based autologous reconstruction (n=37) or implant-based reconstruction (n=20) from August 2015 to January 2016 were injected with 266 mg of liposomal bupivacaine in defined locations along the chest wall, targeting intercostal nerves and incision sites. Patients undergoing autologous reconstruction additionally received a transversus abdominis plane block intraoperatively. All patients received patient controlled analgesia (PCA) and were transitioned to oral pain medication in the early post-operative period. Our previously published data on post-operative narcotic use after breast reconstruction, served as our control cohort. Patient-reported visual analogue pain scales, number of PCA attempts, and oral narcotic use were measured as primary outcomes. We modeled postoperative visual analogue scales, PCA attempts, and postoperative narcotic use over time using spline graphs for comparison between patients receiving LB and those who received traditional pain regimens. results: Total narcotic use in the immediate postoperative period is significantly decreased in patients who underwent autologous-based or implant-based reconstruction and received LB compared to those who did not receive LB (p<0.001). Oral narcotic use in the immediate postoperative period is significantly decreased in patients who underwent autologous-based or implant-based reconstruction and received LB compared to those who did not receive LB (p<0.001). There were no differences in self-reported visual analogue scale scores between treatment and control groups.
ConClusion: This study demonstrates that patients undergoing both implant-based and autologous-based breast reconstruction, who receive regional block with LB, use significantly fewer narcotics.
Current Trends and Controversies in Breast Augmentation
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BaCkground: An ASPS member survey was conducted to study common practices in breast augmentation and assess current attitudes regarding new technologies and current controversies.
Methods:
A 35 item electronic questionnaire was sent to the entire active ASPS membership and was divided into five parts: current controversies, new technologies, common practices, secondary procedures, and member demographics.
results: There were 1,067 respondents. Fifty percent of surgeons never use anatomically shaped implants and another 42 percent do so less than half the time. Autologous fat is infrequently used as a primary technique but more often as a supplemental technique. Approximately seven percent report a case of anaplastic large cell lymphoma in their practice. Eighty-five percent do not use preoperative 3-D imaging. More than half of surgeons use ADM in secondary procedures for capsulorrhaphy buttress, ripples, and capsular contracture. Approximately half do not use insertion funnels. Preoperative sizing with silicone implants, inframammary incisions, partial submuscular pockets, and smooth silicone implants over 300 cc are dominant practice preferences. Postoperative massage is still popular with over half of respondents. Just over half do not use pharmacological agents for capsular contracture and those that do use them at early onset. Capsular contracture and size change were the most frequent reasons for reoperation. Capsular contracture
